13 Best High Volume Stocks to Buy Now

Page 8 of 12

5. Pfizer Inc. (NYSE:PFE)

Average Volume (3-Month): 53.19 million

Number of Hedge Fund Holders: 92

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. The company offers medicines and vaccines in various therapeutic areas, such as cardiovascular & migraine, infectious diseases with unmet medical needs, COVID-19 prevention & treatment, and potential future mRNA & antiviral products.

On April 30, UBS analyst Trung Huynh raised the price target on Pfizer to $25 from $24 while keeping a Neutral rating on the shares due to significant cost savings at the company. For 2025, Pfizer’s priority is improving R&D productivity and advancing its pipeline. As part of this shift, Pfizer decided to discontinue the development of danicopan.

Now the company is building its cardiometabolic pipeline, including obesity, by advancing internal programs like its oral GIPR antagonist (currently in Phase 2) and pursuing external opportunities such as partnerships or acquisitions. Pfizer Inc. (NYSE:PFE) anticipates multiple key pipeline catalysts in 2025, including up to 9 Phase 3 readouts.

Page 8 of 12